OncoMatch/Clinical Trials/NCT05913804
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Is NCT05913804 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies YTS104 Cells for relapsed or refractory multiple myeloma.
Treatment: YTS104 Cells — This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulator
Cannot have received: car-t cell therapy
Exception: undetectable car-t cells or car-t cells below the lower limit of detection
Lab requirements
Blood counts
Good organ function
Kidney function
Good organ function
Liver function
Good organ function
Good organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05913804 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior car-t cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages